FDA 483 - Boehringer Ingelheim Biopharmaceuticals (China) Ltd. - June 09, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Boehringer Ingelheim BioPharmaceuticals (China) Ltd. in Shanghai revealed significant deficiencies across multiple areas of drug substance and drug product manufacturing. Observations included failures in quality unit procedures, visual inspection processes, aseptic manufacturing controls, and data integrity. These issues indicate a lack of adherence to established protocols and inadequate controls, posing potential risks to product quality and sterility.
- Inspection Date
- June 9, 2023
- Product Type
- Drugs
ID · 043bec50-de87-4e6d-a9d9-e057770f067b